AU2012327205B2 - Genetically modified major histocompatibility complex mice - Google Patents

Genetically modified major histocompatibility complex mice Download PDF

Info

Publication number
AU2012327205B2
AU2012327205B2 AU2012327205A AU2012327205A AU2012327205B2 AU 2012327205 B2 AU2012327205 B2 AU 2012327205B2 AU 2012327205 A AU2012327205 A AU 2012327205A AU 2012327205 A AU2012327205 A AU 2012327205A AU 2012327205 B2 AU2012327205 B2 AU 2012327205B2
Authority
AU
Australia
Prior art keywords
human
mhc
mouse
chimeric
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012327205A
Other languages
English (en)
Other versions
AU2012327205A1 (en
Inventor
Cagan Gurer
Lynn Macdonald
Andrew J. Murphy
Sean Stevens
Naxin Tu
Vera VORONINA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2012327205A1 publication Critical patent/AU2012327205A1/en
Application granted granted Critical
Publication of AU2012327205B2 publication Critical patent/AU2012327205B2/en
Priority to AU2016202317A priority Critical patent/AU2016202317B2/en
Priority to AU2018201402A priority patent/AU2018201402C1/en
Priority to AU2021200438A priority patent/AU2021200438B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012327205A 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice Active AU2012327205B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2016202317A AU2016202317B2 (en) 2011-10-28 2016-04-13 Genetically Modified Major Histocompatibility Complex Mice
AU2018201402A AU2018201402C1 (en) 2011-10-28 2018-02-27 Genetically Modified Major Histocompatibility Complex Mice
AU2021200438A AU2021200438B2 (en) 2011-10-28 2021-01-22 Genetically Modified Major Histocompatibility Complex Mice

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552584P 2011-10-28 2011-10-28
US61/552,584 2011-10-28
PCT/US2012/062029 WO2013063340A1 (en) 2011-10-28 2012-10-26 Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202317A Division AU2016202317B2 (en) 2011-10-28 2016-04-13 Genetically Modified Major Histocompatibility Complex Mice

Publications (2)

Publication Number Publication Date
AU2012327205A1 AU2012327205A1 (en) 2013-05-23
AU2012327205B2 true AU2012327205B2 (en) 2016-01-14

Family

ID=47430036

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2012327205A Active AU2012327205B2 (en) 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice
AU2016202317A Active AU2016202317B2 (en) 2011-10-28 2016-04-13 Genetically Modified Major Histocompatibility Complex Mice
AU2018201402A Active AU2018201402C1 (en) 2011-10-28 2018-02-27 Genetically Modified Major Histocompatibility Complex Mice
AU2021200438A Active AU2021200438B2 (en) 2011-10-28 2021-01-22 Genetically Modified Major Histocompatibility Complex Mice

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2016202317A Active AU2016202317B2 (en) 2011-10-28 2016-04-13 Genetically Modified Major Histocompatibility Complex Mice
AU2018201402A Active AU2018201402C1 (en) 2011-10-28 2018-02-27 Genetically Modified Major Histocompatibility Complex Mice
AU2021200438A Active AU2021200438B2 (en) 2011-10-28 2021-01-22 Genetically Modified Major Histocompatibility Complex Mice

Country Status (25)

Country Link
US (7) US8847005B2 (OSRAM)
EP (4) EP2770822B9 (OSRAM)
JP (2) JP6285361B2 (OSRAM)
KR (2) KR102113108B1 (OSRAM)
CN (3) CN108707608A (OSRAM)
AU (4) AU2012327205B2 (OSRAM)
BR (1) BR112014009941B1 (OSRAM)
CA (1) CA2852962C (OSRAM)
CY (3) CY1119283T1 (OSRAM)
DK (3) DK3590332T3 (OSRAM)
ES (3) ES2640241T3 (OSRAM)
HR (3) HRP20220616T1 (OSRAM)
HU (2) HUE034374T2 (OSRAM)
IL (3) IL231895B (OSRAM)
IN (1) IN2014CN03892A (OSRAM)
LT (3) LT3272214T (OSRAM)
MX (2) MX355726B (OSRAM)
PL (3) PL2770822T3 (OSRAM)
PT (3) PT3590332T (OSRAM)
RS (3) RS59997B1 (OSRAM)
RU (1) RU2660564C2 (OSRAM)
SG (3) SG10201909638UA (OSRAM)
SI (3) SI2770822T1 (OSRAM)
SM (3) SMT202200205T1 (OSRAM)
WO (1) WO2013063340A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065730A3 (en) 2006-04-26 2012-09-19 L-3 Communications Security and Detection Systems, Inc. Multi-source surveillance systems
RS55949B1 (sr) 2011-10-28 2017-09-29 Regeneron Pharmaeuticals Inc Humanizovani il-6 i il-6 receptor
SMT202200205T1 (it) 2011-10-28 2022-07-21 Regeneron Pharma Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
WO2014130667A1 (en) * 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
CA2903025C (en) * 2013-03-11 2025-10-07 Regeneron Pharmaceuticals, Inc. TRANSGENIC MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS II MOLECULES
LT3175706T (lt) 2013-09-23 2019-02-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą signalą reguliuojančio baltymo geną
RU2674910C2 (ru) * 2013-10-15 2018-12-13 Регенерон Фармасьютикалс, Инк. Животные с гуманизированным геном il-15
WO2015077071A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
KR102439412B1 (ko) 2014-04-08 2022-09-02 리제너론 파아마슈티컬스, 인크. 인간화된 Fc-감마 수용체를 갖는 비-인간 동물
NO2785538T3 (OSRAM) 2014-05-07 2018-08-04
RS60097B1 (sr) 2014-06-19 2020-05-29 Regeneron Pharma Ne-humane životinje koje imaju humanizovani gen za programiranu ćelijsku smrt 1
RU2017113134A (ru) 2014-09-19 2018-10-19 Регенерон Фармасьютикалз, Инк. Химерные антигенные рецепторы
CA2967823A1 (en) 2014-11-24 2016-06-02 Regeneron Pharmaceuticals, Inc. Non-human animals expressing humanized cd3 complex
SMT201900178T1 (it) 2014-12-05 2019-05-10 Regeneron Pharma Animali diversi dall’uomo aventi un gruppo umanizzato del gene 47 di differenziazione
IL282649B (en) 2014-12-09 2022-07-01 Regeneron Pharma Non-human animals with a humanized gene for differentiation cluster 274
RS64540B1 (sr) 2015-04-06 2023-09-29 Regeneron Pharma Imunski odgovori posredovani humanizovanim t ćelijama kod ne-humanih životinja
PL3376857T3 (pl) 2015-11-20 2021-09-13 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek posiadające humanizowany gen aktywacji limfocytów 3
CN108779159B (zh) * 2016-02-04 2022-12-30 瑞泽恩制药公司 具有经改造的angptl8基因的非人动物
EP3422845B1 (en) 2016-02-29 2021-06-02 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
PT3462853T (pt) 2016-06-03 2023-04-21 Regeneron Pharma Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena
CN116064611A (zh) 2017-11-30 2023-05-05 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
LT3772927T (lt) 2018-03-24 2025-02-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės arba žiurkės, skirtos gaminti terapinius antikūnus prieš peptidų- mhc kompleksus, jų gamybos būdai ir panaudojimas
CN116420679B (zh) 2018-03-26 2025-10-03 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
WO2020018511A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
CN114585744A (zh) * 2019-10-22 2022-06-03 纽约市哥伦比亚大学理事会 转基因猪、其制造方法和用途以及制造人免疫系统小鼠的方法
KR20220110233A (ko) 2019-12-02 2022-08-05 리제너론 파마슈티칼스 인코포레이티드 펩티드-mhc ii 단백질 작제물 및 그의 용도
JP2024512702A (ja) 2021-03-31 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔｃｒβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス
CA3258639A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules to modulate T lymphocyte activity, and their uses
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
CA3265746A1 (en) 2022-09-22 2024-03-28 Regeneron Pharmaceuticals, Inc. GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF A HUMAN CELLULAR IMMUNE SYSTEM
CN120936364A (zh) 2023-01-27 2025-11-11 瑞泽恩制药公司 修饰的弹状病毒糖蛋白及其用途
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070209083A1 (en) * 2001-07-13 2007-09-06 Genoway Cell and transgenic animal modelling human antigenic presentation and their uses

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0437576B1 (en) 1989-07-25 2002-07-03 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
CA2246333A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CA2302779C (en) 1997-09-16 2010-02-02 Oregon Health Sciences University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
IL138579A0 (en) * 1998-03-30 2001-10-31 Res Dev Foundation Corticotropin releasing factor receptor 1-deficient mice
AU1023401A (en) 1999-10-12 2001-04-23 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7067308B1 (en) * 2000-03-28 2006-06-27 Bioagri Corporation Vector for genetically modifying non-human animals
WO2002000933A2 (en) 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050050580A1 (en) 2000-12-13 2005-03-03 Masashi Gotoh Transgenic animal expressing hla-a24 and utilization thereof
AU2002246733B2 (en) 2000-12-19 2007-09-20 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7745690B2 (en) 2004-03-09 2010-06-29 Nagoya Industrial Science Research Institute Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis
PT2767161T (pt) 2004-10-19 2018-04-20 Regeneron Pharma Método para gerar um animal homozigótico para uma modificação genética
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
CN101695587B (zh) * 2009-10-21 2012-08-29 上海中山医疗科技发展公司 一种基因修饰及调控的内皮祖细胞捕获支架的制备方法
EP2593551B1 (en) 2010-07-15 2016-09-14 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
SMT202200205T1 (it) 2011-10-28 2022-07-21 Regeneron Pharma Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
WO2014130667A1 (en) 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CA2903025C (en) 2013-03-11 2025-10-07 Regeneron Pharmaceuticals, Inc. TRANSGENIC MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS II MOLECULES
RS64540B1 (sr) 2015-04-06 2023-09-29 Regeneron Pharma Imunski odgovori posredovani humanizovanim t ćelijama kod ne-humanih životinja

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070209083A1 (en) * 2001-07-13 2007-09-06 Genoway Cell and transgenic animal modelling human antigenic presentation and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ITO, K., et al., Journal of Experimental Medicine, 1996, vol. 183, pages 2635-2644 *
WOODS, A., et al., Journal of Experimental Medicine, 1994, vol. 180, pages 173-181 *

Also Published As

Publication number Publication date
RU2660564C2 (ru) 2018-07-06
EP3590332B1 (en) 2022-02-23
BR112014009941B1 (pt) 2022-11-29
HK1250131A1 (en) 2018-11-30
SG11201400938UA (en) 2014-04-28
US20190239496A1 (en) 2019-08-08
LT2770822T (lt) 2017-10-10
HRP20171327T1 (hr) 2017-11-03
JP6652529B2 (ja) 2020-02-26
CN108401986B (zh) 2021-09-21
AU2018201402C1 (en) 2021-05-06
IL243565A (en) 2017-10-31
HUE048511T2 (hu) 2020-07-28
US20190239497A1 (en) 2019-08-08
CY1122700T1 (el) 2021-03-12
JP2018019700A (ja) 2018-02-08
PL2770822T3 (pl) 2017-11-30
IN2014CN03892A (OSRAM) 2015-10-16
CN108707608A (zh) 2018-10-26
PL3272214T3 (pl) 2020-06-29
US20210195878A1 (en) 2021-07-01
HRP20200305T1 (hr) 2020-06-12
DK3272214T3 (da) 2020-03-02
EP2770822B1 (en) 2017-06-14
EP3272214B1 (en) 2019-11-27
EP3590332A1 (en) 2020-01-08
SMT202000114T1 (it) 2020-03-13
SG10201510056SA (en) 2016-01-28
ES2640241T3 (es) 2017-11-02
IL231895A0 (en) 2014-05-28
WO2013063340A1 (en) 2013-05-02
RU2014116577A (ru) 2015-12-10
EP2770822B9 (en) 2019-12-11
CA2852962A1 (en) 2013-05-02
AU2018201402B2 (en) 2020-10-22
US20240365761A1 (en) 2024-11-07
IL260209B (en) 2019-12-31
CY1119283T1 (el) 2018-02-14
ES2774488T3 (es) 2020-07-21
HUE034374T2 (en) 2018-02-28
ES2914374T3 (es) 2022-06-10
AU2012327205A1 (en) 2013-05-23
SI2770822T1 (sl) 2017-10-30
AU2016202317B2 (en) 2017-11-30
US20150040253A1 (en) 2015-02-05
SI3272214T1 (sl) 2020-04-30
JP2014532411A (ja) 2014-12-08
DK2770822T3 (en) 2017-09-25
IL231895B (en) 2018-07-31
EP4052572A1 (en) 2022-09-07
US9585373B2 (en) 2017-03-07
NZ623146A (en) 2016-06-24
PT2770822T (pt) 2017-09-18
CN108401986A (zh) 2018-08-17
HRP20220616T1 (hr) 2022-06-24
AU2018201402A1 (en) 2018-03-15
MX379060B (es) 2025-03-10
PT3590332T (pt) 2022-05-27
KR102113108B1 (ko) 2020-05-20
MX2014004896A (es) 2014-09-12
RS59997B1 (sr) 2020-04-30
CY1125196T1 (el) 2025-03-28
US10219493B2 (en) 2019-03-05
HK1196999A1 (en) 2015-01-02
AU2021200438B2 (en) 2023-11-02
NZ717130A (en) 2018-07-27
US11219195B2 (en) 2022-01-11
CN104039133B (zh) 2018-05-04
SI3590332T1 (sl) 2022-07-29
PL3590332T3 (pl) 2022-06-13
AU2021200438A1 (en) 2021-02-25
JP6285361B2 (ja) 2018-02-28
RS56330B1 (sr) 2017-12-29
US8847005B2 (en) 2014-09-30
SMT202200205T1 (it) 2022-07-21
PT3272214T (pt) 2020-03-04
KR20140089558A (ko) 2014-07-15
CN104039133A (zh) 2014-09-10
EP2770822A1 (en) 2014-09-03
LT3590332T (lt) 2022-08-10
KR20180132970A (ko) 2018-12-12
AU2016202317A1 (en) 2016-05-05
RU2018115251A (ru) 2019-03-04
US20130111616A1 (en) 2013-05-02
EP4052572B1 (en) 2025-11-26
KR101926442B1 (ko) 2018-12-12
SMT201700437T1 (it) 2017-11-15
MX355726B (es) 2018-04-27
DK3590332T3 (da) 2022-05-23
US20170135329A1 (en) 2017-05-18
LT3272214T (lt) 2020-03-10
BR112014009941A2 (pt) 2020-12-22
SG10201909638UA (en) 2019-11-28
US10986822B2 (en) 2021-04-27
RU2018115251A3 (OSRAM) 2021-09-07
CA2852962C (en) 2022-05-03
RS63220B1 (sr) 2022-06-30
IL260209A (en) 2018-07-31
EP3272214A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
AU2021200438B2 (en) Genetically Modified Major Histocompatibility Complex Mice
US20130185820A1 (en) Genetically Modified Major Histocompatibility Complex Animals
AU2014249148B2 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
HK40080877A (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
HK40017625B (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
HK40017625A (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
HK1250131B (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
HK1196999B (en) Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
NZ717130B2 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MACDONALD, LYNN; MURPHY, ANDREW J.; TU, NAXIN; GURER, CAGAN; VORONINA, VERA AND STEVENS, SEAN

FGA Letters patent sealed or granted (standard patent)